Disclosed are methods of treating a male subject diagnosed with cognitive dysfunction that include administering an estrogenic agent, or a pharmaceutically acceptable salt or complex thereof, to the male subject. Also disclosed is a method of improving cognitive function in a hypogonadal male subject that includes transdermally administering to the male subject a therapeutically effective amount of an estrogenic agent, or a pharmaceutically acceptable salt or complex thereof. Further disclosed is a method of improving cognitive function in a male subject that includes administering to the male subject an estrogenic agent, or a pharmaceutically acceptable salt or complex thereof, at a dosage of about 0.025 to about 1.5 mg/day.

 
Web www.patentalert.com

< RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)

< Treating bone-related disorders with selective androgen receptor modulators

> Metal complex glycogen synthase kinase 3 inhibitors

> Homopiperidine derivatives as NK-1 antagonists

~ 00234